The European Medicines Agency (EMA) contacted a few days ago a possible link between the Janssen vaccine (sometimes also referred to as Johnson & Johnson) and the blood clots that affected some vaccinated.
Blood clots with a low level of platelets have now been classified as a very rare but serious side effect linked to Janssen's vaccine against covid-19.
Sweden would receive delivery with larger quantities of Janssen's vaccine in May.
But as the vaccine is still not recommended for people under 65, FHM has now decided to issue a recommendation to continue pausing Janssen's vaccine for all age groups, the authority writes in a press release.
Blood clots with a low level of platelets have been classified as a very rare but serious side effect linked to Janssen's covid-19 vaccine.
Enough from other manufacturers
The side effects reported have mainly affected younger people.
For people 65 years and older, the risks of developing covid-19 are still considered worse than any side effects from the vaccine, but FHM is awaiting:
- We think it is better to recommend the vaccines that healthcare is now used to using.
People over the age of 65 will still be able to get vaccines of the other three varieties, says Anders Tegnell, state epidemiologist.
Stopped in several countries
Several other countries in Europe and the United States have chosen to pause the use of the vaccine.
To date, nearly seven million Americans have received the Johnson & Johnson vaccine, which is manufactured by the subsidiary Janssen.
The advantage of the vaccine is that only one dose is required to be fully vaccinated.